Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets Growth & Opportunity to 2020

1
Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific
Markets to 2020 - Novel Technologies Show
Considerable Promise in Relapsed/Refractory
Setting
No. Pages 96
Published on September - 2014
2
.
Report Overview
About Non-Hodgkin Lymphoma Therapeutics in
Asia-Pacific Markets to 2020 - Novel Technologies
Show Considerable Promise in Relapsed/Refractory
Setting Research Beam added a report Non-Hodgkin
Lymphoma Therapeutics in Asia-Pacific Markets to
2020 - Novel Technologies Show Considerable
Promise in Relapsed/Refractory Setting. Summary
GBI Research, the leading business intelligence
provider, has released its latest research,
Non-Hodgkin Lymphoma Therapeutics in
Asia-Pacific Markets to 2020 - Novel Technologies
Show Considerable Promise in Relapsed/Refractory
Setting, which provides in-depth insights into
the indication. It gives an estimation of market
size for 2013 along with forecasts until 2020 for
the Asia-Pacific (APAC) region, which comprises
Australia, China, India and Japan. It also covers
disease epidemiology, treatment algorithms,
treatment patterns, in-depth analysis of clinical
trials including failure rates and pipeline
analysis, and analysis of deals relevant to
Non-Hodgkin Lymphoma (NHL). Get Full Details On
http//www.researchbeam.com/non-hodgkin-lymphoma
-therapeutics-in-asia-pacific-to-2020-novel-techno
logies-show-considerable-promise-in-relapsedrefrac
tory-setting-market
3
.
Report Overview
The market in the APAC region was worth an
estimated 1.1 billion in 2013 and is expected to
grow at a Compound Annual Growth Rate (CAGR) of
6.6 to 1.7 billion in 2020. The expected
launches of promising drugs, including novel
protein kinase inhibitors and next-generation
monoclonal antibodies, as well as the continued
use of the current blockbuster, Rituxan/Mabthera,
will be the key growth drivers. The launch of
premium-priced novel glycol-engineered antibody
obinutuzumab kinase inhibitors including
idelalisib and ibrutinib and the mTOR inhibitor
everolimus are also expected to have a
significant impact, as is the anticipated
approval of immunomodulatory agent Revlimid as a
maintenance setting. An increasingly aging
population and a year-on-year increase in the
number of incident cases will provide an
additional boost. However, the recent
implementation of a price ceiling on essential
drugs in India anticipated pricing restrictions
in China and low access, penetration and price
erosion due to generic dominance, especially in
India, stand to curtail the APAC NHL market.
4
.
Report Overview
Scope The report analyzes treatment usage
patterns, market characterization, the pipeline,
and key licensing and co-development deals in the
four APAC markets of Australia, China, India and
Japan. It includes - - A brief introduction to
NHL, including the diseases pathogenesis,
etiology, diagnosis and treatment algorithms -
In-depth analysis of currently marketed drugs for
NHL, examining their safety, efficacy, treatment
patterns and strengths/weaknesses and including a
heat map that compares the drugs in terms of
safety and efficacy - A comprehensive review of
the pipeline for NHL, including individual
analysis of a number of late-stage pipeline drugs
that are likely to enter the market during the
forecast period the pipeline is analyzed on the
basis of Phase distribution, molecule type,
program type, mechanism of action and molecular
target - Additional in-depth analysis of pipeline
drug clinical trials by Phase, trial size, trial
duration and program failure rate for each
molecule type
5
Report Overview
- Multi-scenario forecast data of the market to
2020, taking into account how the market may be
affected by the introduction of new drugs, the
expiry of key patents on current drugs and the
changes in disease epidemiology across the key
developed markets - Discussion of the drivers of
and barriers to market growth - In-depth analysis
of all licensing and co-development deals that
have occurred in the NHL market since 2006
6
Report Overview

•  Reasons to buy
•  The report will enhance your decision-making
  capability by allowing you to -
• - Understand the NHL pipeline and the factors
  that indicate that it is becoming more innovative
• - Examine detailed profiles of promising pipeline
  products and gain an insight into how they are
  likely to compete in the market and who their
  main competitors will be
• - Follow the trends in NHL clinical trial size
  and duration in relation to industry averages and
  assess the potential risk of future developmental
  programs according to mechanism of action by
  considering the recorded clinical trial failure
  rates
• - Observe the potential growth patterns expected
  for the NHL market over the forecast period,
  identify which countries are expected to make the
  biggest contribution to this growth, and devise a
  more effective country - strategy through an
  understanding of key drivers and barriers in the
  NHL market
• - Accelerate and strengthen your market position
  by identifying key companies for strategic
  partnerships
•  

7
Table of Contents
1 Table of Contents1 Table of Contents 61.1
List of Tables 81.2 List of Figures 82
Introduction 102.1 Symptoms 102.2 Etiology
112.3 Pathophysiology 112.4 Diagnosis 122.4.1
Biopsy 122.4.2 Laboratory molecular tests
122.4.3 Imaging tests 132.5 Classification
132.5.1 B-Cell lymphomas 14
8
Table of Contents
2.5.2 T-Cell Lymphomas 162.6 Epidemiology 172.7
Prognosis and Disease Staging 182.7.1 Staging
192.8 Treatment Options 20 2.8.1 Surgery and
Radiation Therapy 202.8.2 Stem Cell
Transplantation 202.8.3 Pharmacological 202.8.4
Treatment Algorithms and Prescribing Habits
22Enquiry about this report _at_
http//www.researchbeam.com/non-hodgkin-lymphoma-t
herapeutics-in-asia-pacific-to-2020-novel-technolo
gies-show-considerable-promise-in-relapsedrefracto
ry-setting-market/enquire-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/non-hodgkin-lymphoma-t
herapeutics-in-asia-pacific-to-2020-novel-technolo
gies-show-considerable-promise-in-relapsedrefracto
ry-setting-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] E-MAIL
sales_at_researchbeam.com